Deutsche Bank Ag\ Axogen, Inc. Transaction History

Deutsche Bank Ag\

$218 Billion
Q2 2024

A detailed history of Deutsche Bank Ag\ transactions in Axogen, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 574,725 shares of AXGN stock, worth $7.93 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

574,725

Previous 579,376 0.8%

Holding current value

$7.93 Million

Previous $4.68 Million 10.99%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$5.67 - $8.06 $26,371 - $37,487	-4,651 Reduced 0.8%	574,725 $4.16 Million
Q1 2024 May 15, 2024	BUY	$6.63 - $10.69 $4,879 - $7,867	736 Added 0.13%	579,376 $4.68 Million
Q4 2023 Feb 14, 2024	BUY	$3.61 - $7.76 $2 Million - $4.29 Million	552,999 Added 2156.7%	578,640 $3.95 Million
Q3 2023 Nov 09, 2023	BUY	$4.68 - $9.26 $15,949 - $31,558	3,408 Added 15.33%	25,641 $128,000
Q2 2023 Aug 14, 2023	SELL	$8.5 - $10.38 $66,716 - $81,472	-7,849 Reduced 26.09%	22,233 $202,000
Q1 2023 May 15, 2023	BUY	$7.53 - $10.95 $53,824 - $78,270	7,148 Added 31.17%	30,082 $284,000
Q4 2022 Feb 13, 2023	BUY	$9.44 - $13.09 $30,755 - $42,647	3,258 Added 16.56%	22,934 $228,000
Q3 2022 Nov 14, 2022	SELL	$8.14 - $12.25 $22,108 - $33,271	-2,716 Reduced 12.13%	19,676 $234,000
Q2 2022 Aug 11, 2022	SELL	$6.99 - $10.0 $146 - $210	-21 Reduced 0.09%	22,392 $184,000
Q1 2022 May 13, 2022	SELL	$7.26 - $10.7 $75,104 - $110,691	-10,345 Reduced 31.58%	22,413 $178,000
Q4 2021 Feb 11, 2022	BUY	$8.8 - $16.0 $10,718 - $19,488	1,218 Added 3.86%	32,758 $307,000
Q3 2021 Nov 04, 2021	SELL	$15.23 - $21.72 $9,625 - $13,727	-632 Reduced 1.96%	31,540 $499,000
Q2 2021 Aug 11, 2021	SELL	$17.8 - $23.5 $21,039 - $27,777	-1,182 Reduced 3.54%	32,172 $695,000
Q1 2021 May 13, 2021	SELL	$17.18 - $22.6 $38,173 - $50,217	-2,222 Reduced 6.25%	33,354 $675,000
Q4 2020 Feb 16, 2021	BUY	$11.5 - $17.96 $39,698 - $61,997	3,452 Added 10.75%	35,576 $636,000
Q3 2020 Nov 12, 2020	SELL	$10.62 - $13.12 $1.44 Million - $1.78 Million	-135,903 Reduced 80.88%	32,124 $374,000
Q2 2020 Aug 13, 2020	BUY	$7.35 - $10.81 $627,587 - $923,022	85,386 Added 103.32%	168,027 $1.55 Million
Q1 2020 May 14, 2020	BUY	$8.38 - $17.34 $517,515 - $1.07 Million	61,756 Added 295.7%	82,641 $859,000
Q4 2019 Feb 14, 2020	SELL	$11.18 - $18.6 $2.64 Million - $4.4 Million	-236,371 Reduced 91.88%	20,885 $372,000
Q3 2019 Nov 14, 2019	SELL	$12.09 - $20.46 $775,126 - $1.31 Million	-64,113 Reduced 19.95%	257,256 $3.21 Million
Q2 2019 Aug 14, 2019	BUY	$18.5 - $25.47 $5.01 Million - $6.9 Million	271,017 Added 538.24%	321,369 $6.36 Million
Q1 2019 May 15, 2019	SELL	$14.62 - $22.13 $2.56 Million - $3.88 Million	-175,124 Reduced 77.67%	50,352 $1.06 Million
Q4 2018 Feb 14, 2019	BUY	$17.09 - $38.25 $177,394 - $397,035	10,380 Added 4.83%	225,476 $4.61 Million
Q3 2018 Dec 21, 2021	BUY	$34.05 - $55.9 $4.68 Million - $7.68 Million	137,418 Added 176.91%	215,096 $7.93 Million
Q3 2018 Nov 14, 2018	SELL	$34.05 - $55.9 $141,750 - $232,711	-4,163 Reduced 5.09%	77,678 $2.86 Million
Q2 2018 Apr 21, 2020	BUY	$36.15 - $52.5 $727,410 - $1.06 Million	20,122 Added 32.6%	81,841 $4.11 Million
Q2 2018 Aug 14, 2018	BUY	$36.15 - $52.5 $504,473 - $732,637	13,955 Added 29.22%	61,719 $3.1 Million
Q1 2018 Oct 18, 2019	BUY	$24.4 - $40.25 $423,193 - $698,096	17,344 Added 57.02%	47,764 $1.74 Million
Q1 2018 May 15, 2018	SELL	$24.4 - $40.25 $985,052 - $1.62 Million	-40,371 Reduced 57.03%	30,420 $1.11 Million
Q4 2017 Feb 14, 2018	SELL	$18.5 - $28.6 $4.45 Million - $6.88 Million	-240,709 Reduced 77.27%	70,791 $2 Million
Q3 2017 Nov 14, 2017	BUY	$14.65 - $19.35 $4.56 Million - $6.03 Million	311,500	311,500 $6.03 Million

Others Institutions Holding AXGN

# of Institutions

129

Shares Held

35.8M

Call Options Held

79.1K

Put Options Held

500

View Full List

About Axogen, Inc.

Ticker AXGN
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 42,283,700
Market Cap $583M
Description
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgic...

More about AXGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account